Create Value with Real World Evidence (RWE)

How can your company make use of the large amount of Real World Data available to generate evidence to support development, market access and safety surveillance?
1 Nov 2022

1 day course


6,150 DKK ex VAT
(app. 827 EUR ex VAT)


This course provides you with an understanding of how Real World Evidence (RWE) can complement evidence from randomised clinical trials and market research. You learn how to choose study design and data sources depending on the purpose of the study and how you may avoid or limit the impact of the sources of error in observational research.

You also learn about the boundaries between interventional clinical trials, observational clinical studies and market research – and the regulatory requirements for the different categories.



  • Real World Data (RWD)
  • Real World Evidence (RWE)
  • Epidemiology
  • Pharmacoepidemiology
  • Observational studies
  • Non-interventional studies
  • Market access


    Do you need help choosing the right course? 

    We are ready to help you at +45 39 27 60 60 or 

    Stay tuned with Atrium's newsletter 

Read more

Course leader(s) & Lecturer(s)

  • Andreas Høiberg Bentsen
    Course leader
    Chief Advisor Team Lead
    DLI Market Intelligence ApS


This course is relevant for you if you want to learn about the importance of and the generation of Real World Evidence. You could be working in the medical industry in areas of health economics, pricing market access, regulatory affairs or pharmacovigilance.

What you will learn

  1. The different opportunities of Real World Data, sometimes called ’Big data’.
  2. How Real World Evidence differs from evidence from randomised clinical trials.
  3. How to generate Real World Data or use existing Real World Data.
  4. How to apply pharmacoepidemiological methods in observational (non-interventional) studies.
  5. How to identify and manage sources of error in observational studies.

What your company will get

  1. An employee who understands the many different aspects of RWE
  2. An employee who understands the pros and cons of various study designs for generating RWE and who is competent in providing input to study designs for various study objectives
  3. An employee who can analyse and evaluate pharmacoepidemiological aspects of observational studies
  4. An employee who can identify sources of error

Course calendar

1 Nov 2022 9:00-16:00


  • Introduction to key concepts and challenges
    • Real World Data (RWD)
    • Real World Evidence (RWE)
    • Customer Perspective
    • Interdisciplinary/academic cooperation
  • From RWD to RWE
  • Epidemiology and Pharmacoepidemiology:
    • Causality
    • Study design: case-control, cohort studies, cross sectionel studies
    • Endpoints
    • Sources for error: bias and confounding
  • Observational studies (Non Interventional Studies)
    • Study designs: selection of design depending on purpose
    • Primary data
    • Secondary data, incl. collaboration partners
    • Study examples
  • Short introduction to the relevant sources of law, e.g. field of application and definitions of relevant terms.
Practical information


Registration deadline
25 Oct 2022
Lersø Parkallé 101
2100 København Ø
1 Nov
Sometimes things change. This is the expected programme.

Course information


Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.

Please familiarize yourself with the mandatory readings before starting the course.


There is no examination for this course.

Course leader(s)

Andreas Høiberg Bentsen
Chief Advisor Team Lead
DLI Market Intelligence ApS


Andreas Høiberg Bentsen
Chief Advisor Team Lead
DLI Market Intelligence ApS

You may also be interested in these courses

WANT TO KNOW MORE or need help?

Contact Client Manager Christina Spangsberg at +45 39 15 09 22

Send me a message